Ownership and insider activity for Elutia Inc (ELUT): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Elutia Inc., a commercial-stage company, focuses on developing drug-eluting biomatrix products for use in surgical reconstruction and related applications. The company operates in two segments, Women’s Health and Cardiovascular. Its lead development programs include NXT-41 and NXT-41x, which are designed as biologic scaffolds combined with local antibiotic delivery. The company provides SimpliDerm, a human acellular dermal matrix used in soft tissue reconstruction.
Price
| Price | $0.81 |
| Market Cap | $36M |
| Exchange | NASDAQ |
| Country | US |
Balance Sheet (10y)
| Year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $2.4M | $2.5M | $39.1M | $30.4M | $17.0M | $19.3M | $13.2M | $36.4M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | $7.2M | $7.2M | $7.2M | $6.0M | $17.6M | $6.0M | $7.0M | $14.6M |
| Inventory | $7.5M | $7.2M | $10.1M | $9.6M | $4.2M | $3.9M | $1.9M | $2.6M |
| Total Current Assets | $18.1M | $18.4M | $59.7M | $47.4M | $50.7M | $31.3M | $26.2M | $55.8M |
| Property, Plant & Equipment | $870000 | $988000 | $1.2M | $1.2M | $565000 | $504000 | $850000 | $5.0M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | $25.3M | $21.9M | $18.5M | $15.1M | $11.7M | $2.6M | $1.5M |
| Total Assets | $47.7M | $44.8M | $82.8M | $67.2M | $68.8M | $43.4M | $36.1M | $62.4M |
| Accounts Payable | $1.6M | $2.5M | $2.1M | $1.6M | $1.4M | $3.2M | $4.1M | $4.8M |
| Short-term Debt | $6.5M | $5.9M | $12.8M | $12.8M | 0 | $3.3M | $1.2M | $4.8M |
| Total Current Liabilities | $13.3M | $18.3M | $26.8M | $26.0M | $42.6M | $43.0M | $37.8M | $25.1M |
| Long-term Debt | $75.9M | $19.6M | $17.8M | $10.4M | $24.3M | $20.4M | $22.6M | $2.8M |
| Total Liabilities | $91.1M | $99.9M | $62.0M | $53.6M | $73.9M | $82.0M | $82.4M | $34.7M |
| Retained Earnings | -$45.0M | -$56.9M | -$80.3M | -$105.1M | -$138.0M | -$175.6M | -$229.6M | -$176.2M |
| Total Equity | -$43.4M | -$55.1M | $20.8M | $13.5M | -$5.0M | -$38.6M | -$46.3M | $27.7M |
| Total Debt | $82.4M | $25.5M | $30.6M | $23.2M | $25.4M | $24.0M | $24.0M | $11.2M |
| Net Debt | $80.0M | $23.0M | -$8.5M | -$7.2M | $8.5M | $4.7M | $10.8M | -$25.2M |
| Working Capital | $4.8M | $172000 | $32.9M | $21.4M | $8.1M | -$11.8M | -$11.6M | $30.7M |
Financial Health
| Debt / Equity | 0.69 |
| Current Ratio | 1.77 |
| Piotroski F-Score | 5 |
| Altman Z-Score | -3.65 |
Profitability
| Return on Equity | 940.81% |
| Return on Invested Capital | -79.27% |
| Return on Assets | 118.69% |
| Gross Margin | 57.82% |
| Operating Margin | -194.03% |
| Net Margin | 426.93% |
Related companies: ANVS · BCAB · CALC · CELU · LTRN · MAIA · PYPD
Explore sector: Healthcare · Biotechnology
More sections of ELUT: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks